Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia

被引:8
|
作者
Palcoux, JB [1 ]
Meyer, M
Jouanel, T
Vanlieferinghen, P
Malpuech, G
机构
[1] Hop Hotel Dieu, Dept Pediat, F-63058 Clermont Ferrand, France
[2] Hop Hotel Dieu, Biochem Lab, F-63058 Clermont Ferrand, France
来源
THERAPEUTIC APHERESIS | 2002年 / 6卷 / 02期
关键词
familial hypercholesterolemia; low-density lipoprotein apheresis;
D O I
10.1046/j.1526-0968.2002.00345.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The laboratory results of five periods of different treatment regimens were compared in a 19-year-old girl with homozygous familial hypercholesterolemia (FH): weekly low-density lipoprotein (LDL) apheresis sessions with dextran sulfate columns (LA 15, Kaneka Corporation, Osaka, Japan) without statin administration: weekly LDL apheresis with polyacrylate columns (DALI Fresenius Adsorber Technology. Bad Homburg. Germany) without statin: LDL apheresis as in Period 2 with 40 mg atorvastatin daily: LDL apheresis as in Period 2 with 80 mg atorvastatin daily and fortnightly LDL apheresis sessions with polyacrilate and administration of 80 mg atorvastatin daily. The five treatments were given in the above order. and each lasted at least 2 months. To compare the effectiveness of the different methods, the blood levels of total cholesterol. LDL-cholesterol and high-density lipoprotein (HDL)-cholesterol were measured before each session, and the percentage decreases in the blood levels of total cholesterol and LDL-cholesterol were recorded during sessions in Periods 1 and 2. In Periods 1 and 2. the biological effectiveness of LDL apheresis was comparable. Atorvastatin (40 mg daily) improved the blood levels of total cholesterol and LDL-cholesterol. but lowered HDL-cholesterol values. Increasing the daily dose of atorvastatin from 40 mg to 80 mg did not significantly improve LDL-cholesterol levels. When the time between two sessions was longer (Period 5). the total cholesterol and LDL-cholesterol values worsened and were comparable to those of Period 2 during which there was no atorvastatin treatment. In this case of homozygous FH. weekly sessions of LDL apheresis in association with atorvastatin at dose of 40 mg per day gave the best results.
引用
收藏
页码:136 / 139
页数:4
相关论文
共 50 条
  • [21] Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
    Matthew K. Ito
    Gerald F. Watts
    Drugs, 2015, 75 : 1715 - 1724
  • [22] Homozygous Familial Hypercholesterolemia Treatment: New Developments
    Blom, Dirk J.
    Marais, A. David
    Raal, Frederick J.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 27 (01)
  • [23] LIPOPROTEIN APHERESIS IN THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    TERUEL, JL
    LASUNCION, MA
    LIANO, F
    HERRERA, E
    ORTUNO, J
    NEFROLOGIA, 1992, 12 (05): : 399 - 403
  • [24] TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA BY PLASMA EXCHANGE
    LEES, RS
    BRESLOW, J
    KING, MEE
    CLINICAL RESEARCH, 1978, 26 (03): : A530 - A530
  • [25] Targeting MTP for the treatment of homozygous familial hypercholesterolemia
    Stefanutti, Claudia
    CLINICAL LIPIDOLOGY, 2014, 9 (03) : 369 - 381
  • [26] Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia
    Ajufo, Ezim
    Cuchel, Marina
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (12): : 933 - 943
  • [27] Homozygous familial hypercholesterolemia
    Genest, J
    Lavoie, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07): : 490 - 490
  • [28] Homozygous Familial Hypercholesterolemia
    Choh, Suhil A.
    Choh, Naseer A.
    Rasool, Akhter
    Yousuf, Roomi
    Qureshi, Umar
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2009, 22 (06): : 573 - 575
  • [29] Homozygous familial hypercholesterolemia
    Alicezah, M. K.
    Razali, R.
    Rahman, T.
    Hoh, B. P.
    Suhana, N. H.
    Muid, S.
    Nawawi, H. M.
    Koshy, M.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2014, 36 (02) : 131 - 137
  • [30] Homozygous Familial Hypercholesterolemia
    Nohara, Atsushi
    Tada, Hayato
    Ogura, Masatsune
    Okazaki, Sachiko
    Ono, Koh
    Shimano, Hitoshi
    Daida, Hiroyuki
    Dobashi, Kazushige
    Hayashi, Toshio
    Hori, Mika
    Matsuki, Kota
    Minamino, Tetsuo
    Yokoyama, Shinji
    Harada-Shiba, Mariko
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2021, 28 (07) : 665 - 678